Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Decitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 known ✓ | P26358 | 5/20 | 0.97 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | GMNN | O75496 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | THPO | P40225 | 1/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | HBB | P68871 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | PNP | P00491 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | PIM1 | P11309 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Decitabine SCHEMBL18402620 | 0.99 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL4006 | 0.99 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL661233 | 0.99 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL117721 | 0.99 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL172264 | 0.99 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL1651086 | 0.99 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL12800474 | 0.99 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL20769771 | 0.99 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL20651628 | 0.99 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL9999636 | 0.99 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424845-A2 | PREPARATION OF DECITABINE | Dr. Reddy's Laboratories, Ltd. (IN) | 2012-03-07 | — | — | EP | disclosed |
| US-20120046457-A1 | PREPARATION OF DECITABINE | DR. REDDY'S LABORATORIES, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2010129211-A2 | PREPARATION OF DECITABINE | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-11-11 | — | — | WO | disclosed |
| US-20100062992-A1 | Salts of 5-Azacytidine | SUPERGEN, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| EP-1765076-A4 | COMPOSITIONS AND FORMULATIONS OF DECITABINE POLYMORPHS AND METHODS OF USE THEREOF | SUPERGEN INC (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-1556010-A4 | PHARMACEUTICAL FORMULATIONS TARGETING SPECIFIC REGIONS OF THE GASTROINTESTINAL TRACT | SUPERGEN INC (US) | 2007-12-05 | — | — | EP | disclosed |
| CN-101014246-A | Compositions and formulations of decitabine polymorphs and methods of use thereof | SUPERGEN INC (US) | 2007-08-08 | — | — | CN | disclosed |
| EP-1793675-A2 | SALTS OF DECITABINE | SuperGen, Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| EP-1788874-A2 | SALTS OF 5-AZACYTIDINE | SuperGen, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-1765076-A1 | COMPOSITIONS AND FORMULATIONS OF DECITABINE POLYMORPHS AND METHODS OF USE THEREOF | SuperGen, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006037024-A2 | SALTS OF DECITABINE | SUPERGEN, INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060074046-A1 | Oral administration of decitabine salt | SUPERGEN, INC. | 2006-04-06 | — | — | US | disclosed |
| WO-2006034154-A2 | SALTS OF 5-AZACYTIDINE | SUPERGEN, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060069060-A1 | Salts of decitabine | SUPERGEN, INC. | 2006-03-30 | — | — | US | disclosed |
| US-20060063735-A1 | Salts of 5-azacytidine | SUPERGEN, INC. (US) | 2006-03-23 | — | — | US | disclosed |
| WO-2006017278-A1 | COMPOSITIONS AND FORMULATIONS OF DECITABINE POLYMORPHS AND METHODS OF USE THEREOF | SUPERGEN, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20060014949-A1 | Compositions and formulations of decitabine polymorphs and methods of use thereof | SUPERGEN INC. (US) | 2006-01-19 | — | — | US | disclosed |
| EP-1556010-A2 | PHARMACEUTICAL FORMULATIONS TARGETING SPECIFIC REGIONS OF THE GASTROINTESTINAL TRACT | SuperGen, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20040162263-A1 | Pharmaceutical formulations targeting specific regions of the gastrointesinal tract | SUPERGEN, INC., A DELAWARE CORPORATION | 2004-08-19 | — | — | US | disclosed |
| WO-2004041195-A2 | PHARMACEUTICAL FORMULATIONS TARGETING SPECIFIC REGIONS OF THE GASTROINTESTINAL TRACT | SUPERGEN, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074046-A1 | Oral administration of decitabine salt | DNMT3A, TET2, TET3 | DNMT1 5/4885ADRB1 4217/4885LMNA 2871/4885 |
| US-20100062992-A1 | Salts of 5-Azacytidine | AZI2, TET2, DNMT3A | DNMT1 4/4885ADRB1 4281/4885LMNA 3648/4885 |
| US-20120046457-A1 | PREPARATION OF DECITABINE | DNMT3A, DNMT1, DNMT3B | DNMT1 2/4885ADRB1 4149/4885LMNA 742/4885 |
| US-20060069060-A1 | Salts of decitabine | DNMT3A, TET2, DNMT1 | DNMT1 3/4885ADRB1 4545/4885LMNA 2268/4885 |
| US-20060063735-A1 | Salts of 5-azacytidine | AZI2, TET2, DNMT3A | DNMT1 4/4885ADRB1 4281/4885LMNA 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.